Abstract
Clinical genetic studies propose a strong genetic contribution to the pathogenesis of anxiety disorders with a heritability of about 30-67%. The present review will give an overview of linkage studies, association studies and genome-wide association studies (GWAS) yielding support for some candidate genes. Additionally, first evidence for gene-environment interactions between candidate genes of anxiety disorders and stressful life events will be reported. On a systems level, neural activation correlates of anxiety-relevant emotional processing and neurophysiological measures such as peripheral sympathetic activity or the startle reflex have been shown to be potentially driven by vulnerability genes of anxiety disorders. Promising current approaches to further dissect the genetic underpinnings of anxiety disorders such as next generation sequencing, epigenetic analyses and pharmaco-/ psychotherapy-genetics will be presented. Genetic research in anxiety disorders will be discussed with respect to its potential benefit for future efforts to develop innovative and individually tailored therapeutic approaches for patients with anxiety disorders.
Keywords: Linkage, association, genome-wide association, gene-environment interaction, imaging genetics, epigenetics, pharmacogenetics
Current Pharmaceutical Design
Title:Genetics of Anxiety Disorders - Status Quo and Quo Vadis
Volume: 18 Issue: 35
Author(s): Katharina Domschke and Jurgen Deckert
Affiliation:
Keywords: Linkage, association, genome-wide association, gene-environment interaction, imaging genetics, epigenetics, pharmacogenetics
Abstract: Clinical genetic studies propose a strong genetic contribution to the pathogenesis of anxiety disorders with a heritability of about 30-67%. The present review will give an overview of linkage studies, association studies and genome-wide association studies (GWAS) yielding support for some candidate genes. Additionally, first evidence for gene-environment interactions between candidate genes of anxiety disorders and stressful life events will be reported. On a systems level, neural activation correlates of anxiety-relevant emotional processing and neurophysiological measures such as peripheral sympathetic activity or the startle reflex have been shown to be potentially driven by vulnerability genes of anxiety disorders. Promising current approaches to further dissect the genetic underpinnings of anxiety disorders such as next generation sequencing, epigenetic analyses and pharmaco-/ psychotherapy-genetics will be presented. Genetic research in anxiety disorders will be discussed with respect to its potential benefit for future efforts to develop innovative and individually tailored therapeutic approaches for patients with anxiety disorders.
Export Options
About this article
Cite this article as:
Domschke Katharina and Deckert Jurgen, Genetics of Anxiety Disorders - Status Quo and Quo Vadis, Current Pharmaceutical Design 2012; 18 (35) . https://dx.doi.org/10.2174/138161212803530781
DOI https://dx.doi.org/10.2174/138161212803530781 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Efficacy and Mechanisms of Action of Lithium Augmentation in Refractory Major Depression
Current Pharmaceutical Design Neuropeptide Y: Role in Emotion and Alcohol Dependence
CNS & Neurological Disorders - Drug Targets Current and Future Drugs for Appetite Regulation and Obesity Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Interactions Between the Sympathetic Nervous System and Angiotensin System in Renovascular Hypertension
Current Hypertension Reviews Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
Current Pharmaceutical Design Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Important Role of Relaxation Techniques in Immune Functions, Glycemic Control, and Stress in Diabetic Patients with COVID-19: A Review
Current Diabetes Reviews The Impact of Substance P on the Pathogenesis of Insulin Resistance Leading to Gestational Diabetes
Current Pharmaceutical Biotechnology In vivo Piroxicam Metabolites: Possible Source for Synthesis of Central Nervous System (CNS) Acting Depressants
Central Nervous System Agents in Medicinal Chemistry Steroid Regulation of Drug-Metabolizing Cytochromes P450
Current Drug Metabolism Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Is There Any Scientific Basis of Hawan to be Used in the Alzheimer’s Disease Prevention/Cure?
Current Traditional Medicine Beyond the Synapse and Hebb's Rule: Is the Rest of the Neuron More Important for Psychiatric Disorders?
Current Psychiatry Reviews D2 Receptor Partial Agonists: Treatment of CNS Disorders of Dopamine Function
Current Topics in Medicinal Chemistry Disruption of Circadian Rhythms and Delirium, Sleep Impairment and Sepsis in Critically ill Patients. Potential Therapeutic Implications for Increased Light-Dark Contrast and Melatonin Therapy in an ICU Environment
Current Pharmaceutical Design Effects of Novel Monoamine Oxidases and Cholinesterases Targeting Compounds on Brain Neurotransmitters and Behavior in Rat Model of Vascular Dementia
Current Pharmaceutical Design Modulation of Neutrophil Function by Hormones
Current Immunology Reviews (Discontinued) Ghrelin and the Brain-gut Axis as a Pharmacological Target for Appetite Control
Current Pharmaceutical Design Potential Health Hazards for Cumulative Exposures to Phthalates and Ionizing Radiation in High-Risk Pediatric Population
Mini-Reviews in Medicinal Chemistry Neural Pathways and Neuropeptides Mediate the Therapeutic Actions of DPP IV Inhibitors in Type-2 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)